PROVECTUS BIOPHARMS (PVCT) analyst actions
Rating and price-target actions on PVCT in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the PVCT overview →
2 measured PVCT analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer | Press release | -10.48% | +0.00% | |
| Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation | Press release | +0.00% | +7.40% |
Keep exploring
More PVCT: earnings → · SEC filings → · PVCT overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| INNOVATE BIOPHARMACEUTICALS (INNT) | 220 | -0.77% | 38% |
| OWC PHARMS RESEARCH CORP (OWCP) | 220 | +0.09% | 52% |
| TG Therapeutics, Inc. (TGTX) | 220 | -0.06% | 47% |
| Lipocine Inc. (LPCN) | 219 | +0.34% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.